<DOC>
	<DOCNO>NCT00051142</DOCNO>
	<brief_summary>The purpose study evaluate safety IOP-lowering efficacy Travoprost ( 0.004 % ) compare Latanoprost ( 0.005 % ) patient chronic open-angle glaucoma ocular hypertension .</brief_summary>
	<brief_title>A Safety Efficacy Study Travoprost 0.004 % Compared Latanoprost 0.005 % Patients With Open-Angle Glaucoma ( OAG ) Ocular Hypertension ( OHT )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<criteria>Adult patient race either sex openangle glaucoma ( without pigment dispersion pseudoexfoliation component ) ocular hypertension .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Glaucoma</keyword>
	<keyword>POAG</keyword>
	<keyword>OAG</keyword>
	<keyword>OHT</keyword>
</DOC>